GlaxoSmithKline PLC — Director's Dealing 2018

Feb 16, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1940F

GlaxoSmithKline PLC

16 February 2018

GlaxoSmithKline plc (the 'Company')

Conditional Share Awards

This notification sets out the vesting details of awards over Ordinary Shares and American Depositary Shares ('ADS') made in 2015 under the GlaxoSmithKline Performance Share Plan ('PSP'), which were subject to relevant business performance conditions.  The three-year performance period for the 2015 awards commenced on 1 January 2015 and ended on 31 December 2017. 

The performance measure vesting details for those Persons Discharging Managerial Responsibilities ('PDMRs') who received awards in 2015 are set out in the following table. 

		Outcome and Vesting Level
Portion of the Award	Measure and Outcome	% of maximum	% of award
1/3rd	Adjusted Free Cash Flow - For the three-year period, the Company achieved Adjusted Free Cash Flow calculated in accordance with the principles for the measure of £12.47bn which is above the threshold level of £11.48bn.	63	21
1/3rd	Total Shareholder Return - For the three years ending 31 December 2017, the Company's Total Shareholder Return ranked 5th, which is above the threshold vesting level against a comparator group of 10 global pharmaceutical companies including GSK.	44	14.67
1/3rd	R&D New Products - For the three-year period, the Company achieved New Product sales calculated in accordance with the principles for the measure of £11.266bn, which is above the maximum vesting level of £7.912bn (the threshold level was £6.474bn).	100	33.33
	Total vesting for 2015 award Lapsed		69% 31%

The notifications that follow are for awards made to PDMRs and detail the PSP conditional awards that vested, including dividends accrued, on 15 February 2018.  The balance of the award made to each PDMR has lapsed.

The closing share prices of an Ordinary Share and of an ADS of GlaxoSmithKline plc at the point of vesting on 15 February 2018 were £13.004 and $37.31.

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary Shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£0.00	91,430
£0.00	47,391

d)

Aggregated information

Aggregated volume Price

138,821

£0.00

e)

Date of the transaction

2018-02-15

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Connor

b)

Position/status

President, Global Manufacturing & Supply

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary Shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£0.00	71,160

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2018-02-15

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Debruyne

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary Shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£0.00	18,203

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2018-02-15

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary Shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.  These shares are subject to a two-year holding period to end in 2020.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£0.00	154,763

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2018-02-15

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary Shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan. 

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£0.00	34,502

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2018-02-15

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

GlaxoSmithKline plc American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

The number of ADSs vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan and which were made to compensate for the value of awards forfeited on completion of the Joint Venture with Novartis.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
$0.00	24,345
$0.00	4,871

d)

Aggregated information

Aggregated volume Price

29,216

$0.00

e)

Date of the transaction

2018-02-15

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary Shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£0.00	56,605

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2018-02-15

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary Shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£0.00	75,473

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2018-02-15

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary Shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£0.00	43,667

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2018-02-15

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Troy

b)

Position/status

SVP & General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

GlaxoSmithKline plc American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

The number of ADSs vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
$0.00	66,334

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2018-02-15

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr P Vallance

b)

Position/status

Outgoing President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary Shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£0.00	156,984

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2018-02-15

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs V Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each 'Ordinary Shares'

ISIN: GB0009252882

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£0.00	9,667

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2018-02-15

f)

Place of the transaction

London Stock Exchange (XLON)

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHDQLFFVLFLBBX